Analyst Reco. Aligos Therapeutics, Inc.

Equities

ALGS

US01626L1052

Market Closed - Nasdaq Other stock markets 21:00:00 21/06/2024 BST			5-day change	1st Jan Change
0.451 ^USD	+8.39%		-9.80%	-32.08%

05-22	Aligos Therapeutics, Inc. Announces Resignation of Jack Nielsen as Member of the Board of Directors	CI
05-21	Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2A Herald Study for the Treatment of Mash	CI

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Piper Sandler Adjusts Price Target on Aligos Therapeutics to $7 From $3, Maintains Overweight Rating	17/01/23	MT
Piper Sandler Upgrades Aligos Therapeutics to Overweight From Neutral, Adjusts Price Target to $3 From $2	06/01/23	MT
Jefferies Upgrades Aligos Therapeutics to Buy From Hold, Adjusts Price Target to $3 From $2.50	06/01/23	MT
SVB Securities Adjusts Aligos Therapeutics' Price Target to $2 From $3, Keeps Market Perform Rating	03/11/22	MT
Cantor Fitzgerald Downgrades Aligos Therapeutics to Neutral From Overweight, Adjusts Price Target to $1.20 From $11	08/08/22	MT
SVB Leerink Cuts Aligos Therapeutics to Market Perform From Outperform, Price Target to $3 From $7	05/05/22	MT
Jefferies Lowers Price Target for Aligos Therapeutics to $2.50 From $5, Maintains Hold Rating	23/03/22	MT
SVB Leerink Adjusts Aligos Therapeutics' Price Target to $7 from $11, Keeps Outperform Rating	23/03/22	MT
Piper Sandler Cuts Aligos Therapeutics to Neutral From Overweight, Price Target to $4 From $15	23/03/22	MT
SVB Leerink Adjusts Aligos Therapeutics' Price Target to $11 from $10, Keeps Outperform Rating	11/03/22	MT
SVB Leerink Adjusts Aligos Therapeutics' Price Target to $10 from $15, Maintains Outperform Rating	16/02/22	MT
Jefferies Downgrades Aligos Therapeutics to Hold From Buy, Adjusts Price Target to $5 From $20	07/01/22	MT
SVB Leerink Adjusts Aligos Therapeutics' Price Target to $15 from $29, Keeps Outperform Rating	07/01/22	MT
JPMorgan Lowers Aligos Therapeutics to Neutral From Overweight, Price Target to $12 From $30	07/01/22	MT
ALIGOS THERAPEUTICS : SVB Leerink Starts Aligos Therapeutics at Outperform with $29 Price Target	09/09/21	MT
ALIGOS THERAPEUTICS : Piper Sandler Initiates Coverage on Aligos Therapeutics With Overweight Rating, $47 Price Target	17/05/21	MT
ALIGOS THERAPEUTICS : Piper Sandler Adjusts Price Target on Aligos Therapeutics to $40 From $35, Maintains Overweight Rating	24/03/21	MT
ALIGOS THERAPEUTICS : Jefferies & Co Adjusts Aligos Therapeutics PT to $30 From $26, Maintains Buy Rating	21/12/20	MT
ALIGOS THERAPEUTICS : Cantor Fitzgerald Starts Aligos Therapeutics at Overweight With $28 Price Target	10/11/20	MT
ALIGOS THERAPEUTICS : Piper Sandler Starts Aligos Therapeutics at Overweight With $35 Price Target	10/11/20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Aligos Therapeutics, Inc.

Equities

ALGS

US01626L1052

Analyst Reco.

Filters